AIM: To evaluate the bioequivalence of the two rivaroxaban tablets in Chinese healthy subjects. METHODS: Twenty-eight subjects under fasting status and twenty-eight subjects under fed status were enrolled in the study. This study was designed as a four period, fully repetitive, crossover study. All subjects were administered test (T) and reference (R) rivaroxaban tablets (10 mg) under fasting and fed condition respectively. Liquid chromatography - tandem mass spectrometry was used to detect the concentrations of rivaroxaban in plasma. WinNonlin 7.0 was used to calculate the main pharmacokinetic parameters (PK) and to evaluate the bioequivalence. RESULTS: In fasting group, the main pharmacokinetic parameters of T and R preparation were as follows: Cmax were(186.57±56.41) and (187.61±50.89) ng/mL; AUC0-t were (1 156.21±335.85) and (1 177.59±343.72) h·ng·mL-1; AUC0-∞ were (1 235.77±384.03) and (1 223.53±392.10) ng·h·mL-1. The 90% confidential interval (CI) of the three main parameters were 90.81%-105.67%, 92.83%-103.85% and 95.04%-107.13%. The upper limit of the 90% CI for the test- to- reference ratio of the within-subject of Cmax, AUC0-t  and  AUC0-∞ were 1.56, 1.41 and 1.73. In fed group, the main pharmacokinetic parameters of T and R preparation were as follows: Cmax were (207.81±45.26) and (211.04±36.62) ng/mL; AUC0-t were (1 271.26±260.92) and (1 233.23±201.85) h·ng·mL-1; AUC0-∞ were (1 290.76±264.90) and (1 251.68±203.73) ng·h·mL-1. The 90% CI of the three main parameters were 92.82%-102.28%, 97.68%-106.68% and 97.71%-106.68%. The upper limit of the 90% CI for the test- to- reference ratio of the within-subject of Cmax, AUC0-t and AUC0-∞ were 1.76, 1.47 and 1.47. CONCLUSION:The two preparations of rivaroxaban tablets were bioequivalent.